INVA vs AAPG
Side-by-side comparison of price performance, valuation, growth, profitability, analyst targets and technical trend.
INVA · Innoviva$19.10 ▼ 0.73%
AAPG · Ascentage Pharma$15.43 ▲ 1.98%
One year, rebased to 100
Each line starts at 100 so growth is directly comparable
- INVA -8.5%
- AAPG -52.4%
Head to head
| Metric | INVA | AAPG |
|---|---|---|
| Price | $19.10 | $15.43 |
| Change today | ▼ 0.73% | ▲ 1.98% |
| Market cap | $1.36B | $1.44B |
| Return, 3 months | -7.6% | -18.2% |
| Return, year to date | -4.5% | -41.2% |
| Return, 1 year | -8.4% | -51.4% |
| P/E (TTM) | 8.1 | – |
| P/B | 1.2 | 17.3 |
| P/E percentile vs own 5y | 25th | 99th |
| Dividend yield | – | – |
| Revenue growth (YoY, latest qtr) | +19.3% | -41.5% |
| Net profit growth (YoY) | -231.0% | -206.4% |
| Gross margin | 78.2% | 93.9% |
| Operating margin | 36.9% | -216.7% |
| Net margin | 81.2% | -228.5% |
| Return on equity | 36.7% | -240.3% |
| Analyst target vs. price | +105.5% | +172.2% |
| Analyst buy share | 100% | 100% |
| RSI (14) | 31 | 52 |
| 30-day volatility | 36.5% | 72.0% |
| Max drawdown, 1 year | -21.2% | -61.0% |
| Trend read | Strong downtrend | Leaning bullish |
| Analyst consensus | Buy | Buy |
Green cells mark the best value in each row where "better" is clear-cut (lower P/E, higher margin). That is a reading of the numbers, not a recommendation. Financials are in each company's reporting currency.
What the numbers say
- AAPG is the largest of the group by market value.
- INVA has returned the most over the past year.
- INVA is growing revenue fastest.
- INVA keeps the most profit per dollar of sales.
- INVA has been the calmest stock over the last 30 days.